Next 10 |
home / stock / ions / ions articles
U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of RXO, Inc.. (NYSE:RXO) share...
Friday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced results from the Phase 3 OASIS-HAE and OASISplus studies of donidalorsen in patients with...
On Thursday, the European Commission granted marketing authorization under exceptional circumstances and maintained orphan designation for Biogen I...
Thursday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Biogen Inc (NASDAQ:BIIB) decided to terminate the development of BII...
Ionis Pharmaceuticals Inc (NASDAQ:IONS) released results from a Phase 2 study of ION224, an investigational DGAT2 antisense inhibitor for meta...
Biogen Inc (NASDAQ:BIIB) is pulling the plug on its Aduhelm Alzheimer’s disease drug more than two years after the drug came into the limeli...
Monday, Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced topline results for the Phase 3 OASIS-HAE study of donidalorsen in people with&...
Friday, the FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplontersen) ...
Friday, FDA approved AstraZeneca Plc (NASDAQ: AZN) and Ionis Pharmaceuticals Inc's (NASDAQ: IONS) Wainua (eplonte...
News, Short Squeeze, Breakout and More Instantly...
Ionis Pharmaceuticals Inc. Company Name:
IONS Stock Symbol:
NASDAQ Market:
Ionis Pharmaceuticals Inc. Website:
2024-06-27 11:30:07 ET Wells Fargo analyst issues BUY recommendation for IONS on June 27, 2024 09:00AM ET. The previous analyst recommendation was Buy. IONS was trading at $47.5097 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current a...
2024-06-27 11:30:06 ET Oppenheimer analyst issues UNDERPERFORM recommendation for IONS on June 27, 2024 09:00AM ET. The previous analyst recommendation was Underperform. IONS was trading at $47.5097 at issue of the analyst recommendation. The overall analyst consensus : ...
Ionis announces olezarsen FCS New Drug Application accepted for Priority Review and enrollment in Phase 3 sHTG program completed PR Newswire – Olezarsen PDUFA date set for December 19, 2024 for treatment of familial chylomicronemia syndrome – – ...